Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 14;13(2):290.
doi: 10.3390/cancers13020290.

Significance of Lauren Classification in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany

Rebekka Schirren  1 , Alexander Novotny  1 , Christian Oesterlin  1 , Julia Slotta-Huspenina  2 , Helmut Friess  1 , Daniel Reim  1
Affiliations

Significance of Lauren Classification in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany

Rebekka Schirren et al. Cancers (Basel). .

Abstract

Background: the purpose of this analysis was to analyze the outcomes of multimodal treatment that are related to Lauren histotypes in gastro-esophageal cancer (GEC).

Methods: patients with GEC between 1986 and 2013 were analyzed. Uni- and multivariate regression analysis were performed to identify predictors for overall survival. Lauren histotype stratified overall survival (OS)-rates were analyzed by the Kaplan-Meier method. Further, propensity score matching (PSM) was performed to balance for confounders.

Results: 1290 patients were analyzed. After PSM, the median survival was 32 months for patients undergoing primary surgery (PS) and 43 months for patients undergoing neoadjuvant chemotherapy (nCTx) ahead of surgery. For intestinal types, median survival time was 34 months (PS) vs. 52 months (nCTx+surgery) p = 0.07, 36 months (PS) vs. (31) months (nCTx+surgery) in diffuse types (p = 0.44) and 31 months (PS) vs. 62 months (nCTx+surgery) for mixed types (p = 0.28). Five-/Ten-year survival rates for intestinal, diffuse, and mixed types were 44/29%, 36/17%, and 43/33%, respectively. After PSM, Kaplan-Meier showed a survival benefit for patients undergoing nCTx+surgery in intestinal and mixed types.

Conclusion: the Lauren histotype might be predictive for survival outcome in GEC-patients after neoadjuvant/perioperative chemotherapy.

Keywords: Lauren histotype; gastric/gastroesophageal cancer; perioperative chemotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Survival curves for Lauren intestinal subtype after PSM stratified by surgery only vs. chemotherapy plus surgery.
Figure 2
Figure 2
Survival curves for Lauren mixed subtype after PSM stratified by surgery only vs. chemotherapy plus surgery.
Figure 3
Figure 3
Survival curves for Lauren diffuse subtype after PSM stratified by surgery only vs. chemotherapy plus surgery.
Figure 4
Figure 4
Survival curves for intestinal subtype after PSM differentiated by responders, non-responders, and surgery only.
Figure 5
Figure 5
Survival curves for diffuse subtype after PSM differentiated by responders, non- responders and surgery only.
Figure 6
Figure 6
Survival curves for mixed subtype after PSM differentiated by responders, non-responders and surgery only.
See this image and copyright information in PMC

References

    1. Guggenheim D.E., Shah M.A. Gastric cancer epidemiology and risk factors. J. Surg. Oncol. 2013;107:230–236. doi: 10.1002/jso.23262. - DOI - PubMed
    1. Lagarde S.M., ten Kate F.W., Reitsma J.B., Busch O.R.C., van Lanschot J.J.B. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J. Clin. Oncol. 2006;24:4347–4355. doi: 10.1200/JCO.2005.04.9445. - DOI - PubMed
    1. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J.H., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006;355:11–20. doi: 10.1056/NEJMoa055531. - DOI - PubMed
    1. Ychou M., Boige V., Pignon J.-P., Conroy T., Bouche O., Lebreton G., Ducourtieux M., Bedenne L., Fabre J.-M., Saint-Aubert B., et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. J. Clin. Oncol. 2011;29:1715–1721. doi: 10.1200/JCO.2010.33.0597. - DOI - PubMed
    1. Van Hagen P., Hulshof M.C., van Lanschot J.J., Steyerberg E.W., van Berge Henegouwen M.I., Wijnhoven B.P., Richel D.J., Nieuwenhuijzen G.A., Hospers G.A., Bonenkamp J.J., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 2012;366:2074–2084. doi: 10.1056/NEJMoa1112088. - DOI - PubMed

LinkOut - more resources